VEGF polymorphisms are not associated with an increased risk of developing renal cell carcinoma in Spanish population

ABSTRACT. We conducted a case-control study in a Chinese population, and assessed whether the VEGF -634G/C, +936C/T, and +1612G/A polymorphisms could affect the risk of osteosarcoma and its association with environmental factors. A total of 180 consecutive osteosarcoma patients and 360 controls were included in our study. The genotypes of VEGF -634G/C, +936C/T, and +1612G/A were determined by the polymerase chain reaction-restriction fragment length polymorphism assay. Conditional logistic regression analyses showed that subjects carrying the GG genotype and the G allele of VEGF -634G/C were significantly associated with increased risk of osteosarcoma compared to those with the CC genotype; the ORs (95%CIs) were 2.28 (1.31-3.96) and 1.51 (1.16-1.97) for the GG genotype and G allele, respectively. We found that the GG genotype of VEGF -634G/C was associated with a significantly increased risk 8284 G. Zhang et al. ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (3): 8283-8289 (2015) of osteosarcoma in patients of either gender with younger age and a family history of cancer. In summary, this study found that the VEGF -634G/C gene polymorphism was associated with an increased risk of osteosarcoma.

Section: Discussionmentioning

confidence: 99%

Investigation of the role of VEGF gene polymorphisms in the risk of osteosarcoma

Zhang¹,

Bai²,

Zhang³

et al. 2015

“…Genes implicated in angiogenesis may be indicators of the progression and important prognostic factors in various cancers, such as pancreatic, gastric, lung, and renal cell cancer (Sáenz-López et al, 2013;Sivaprasad et al, 2013;Oh et al, 2013;Sun et al, 2013). VEGF, a growth factor that regulates angiogenesis, is regarded to be the most potent stimulatory cytokine regulating tumor angiogenesis and an important factor in metastasis, survival, and tumor spread (Salven et al, 1997 the promoter region of VEGF may play a role in altering gene transcription and expression (Absenger et al, 2013;Oh et al, 2013).…”

Section: Discussionmentioning

confidence: 99%

Polymorphisms of vascular endothelial growth factor on prognosis in hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization treatment

Song¹,

Wang²,

Li³

et al. 2014

ABSTRACT. We conducted a cohort study to investigate the prognostic significance of vascular endothelial growth factor (VEGF) polymorphisms in hepatocellular carcinoma (HCC) patients after transcatheter arterial chemoembolization (TACE). In total, 156 patients with histologically confirmed HCC within 2 months were collected from January 2007 to January 2008. The genotypes of VEGF-2578C/A, -1154G/A, -634C/G, and -1498T/C were determined from blood extracted using a blood kit on a 384-well plate. The survival rate at 5 years was 55.47%. Multivariate analysis revealed that only tumornode-metastasis (TNM) stage, metastasis, and the VEGF-2578 AA and -1154 AA genotypes were independent prognostic factors. Patients with TNM stage III-IV and metastasis showed a greatly increased risk of death from HCC, with hazard ratios (HRs) [95% confidence interval (CI)] of 3.64 (1.67-6.79) and 2.91 (1.30-6.27), respectively. Moreover, the VEGF-2578 AA and -1154 AA genotypes showed a significantly increased risk of death compared with the wild-type genotype (HR 8947 ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 13 (4): 8946-8953 (2014) VEGF polymorphism and HCC prognosis = 3.65, 95%CI = 1.35-11.13; HR = 7.13, 95%CI = 1.46-65.8). These results will be helpful for predicting clinical outcomes of HCC patients.

“…Given the possible influence of VEGF levels on treatment efficacy in RCC, VEGF polymorphisms may have an association with risk of RCC patients. Two previous studies conducted in Japan and Spain demonstrated that VEGF polymorphisms may have effects on RCC progression or prognosis (Kawai et al, 2007;Sáenz-López et al, 2013). But the results are inconsistent, and another study has suggested that VEGF gene polymorphisms are not associated with RCC risk (Matthew et al, 2002).…”

Section: Introductionmentioning

confidence: 99%

Predictive role of vascular endothelial growth factor polymorphisms in the survival of renal cell carcinoma patients

Yang

Chen

2014

ABSTRACT. We conducted a study to investigate the possible role of the vascular endothelial growth factor (VEGF) polymorphisms -2578C/A, -1154G/A and -634C/G and clinical factors in renal cell carcinoma (RCC) prognosis in a cohort of 336 RCC cases. A total of 336 patients with RCC were recruited from PLA General Hospital between January 2004 and December 2005. All patients were followed up until December 2010, and no patient was lost to follow-up. The follow-up time of this study was 60 months. At the time of analysis, a total of 210 died during the follow-up. The median overall survival for patients was 29.1 months (95%CI = 17.1 to 41.3 months), and the 5-year survival rate for the patients was 37.5%. Our study showed that Karnofsky performance status ≥60 could delay death from RCC, with HR (95%CI) of 0.57 (0.39-0.84). Patients with anemia, platelet count >400 x 10 9 /L, neutrophilia and lymphocytes >160 g/L had increased risk of death from RCC, with HR (95%CI) of 1.84 (1.18-2.96), 2.01 (1.27-3.25), 1.65 (1.03-2.56) and 1.49 (0.99-2.71), respectively. The VEGF -2578AA and -1154AA genotypes were significantly associated with a poor overall survival of RCC patients, with HR (95%CI) of 2.41 (1.32-5.13) and 3.77 (1.42-15.67), respectively. In conclusion, our study presented the factors regarding the prognosis of RCC patients, and high platelet and neutrophil counts, low lymphocytes, and VEGF -2578C/A and -1154G/A polymorphisms were shown to be independent factors for a lower prognosis of RCC patients.